Skip to main content
Fig. 3 | BMC Health Services Research

Fig. 3

From: Health professionals’ preferences with the use of pegfilgrastim on-body injector at oncology centers in 8 cities in Colombia

Fig. 3

Preferences regarding use of Pegfilgrastim in three hypothetical clinical cases

At least 60% of HCP reported a preference for the use of Neulastim OBI for the administration of Pegfilgrastim for all hypothetical cases presented, followed by having the patients return after 24 h of myelosuppressive therapy administration for a Pegfilgrastim injection

Back to article page

BMC Health Services Research

ISSN: 1472-6963

Contact us